Informations générales (source: ClinicalTrials.gov)
MYeloma Resistance And Clonal Evolution (MYRACLE)
Observational [Patient Registry]
Nantes University Hospital (Voir sur ClinicalTrials)
février 2019
février 2029
29 juin 2024
Multiple Myeloma (MM) is often associated with progression, temporary response to therapy
and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is
classified as an incurable disease, therapeutic resistance is of great interest. However,
knowledge about the biological mechanisms underlying resistance associated with MM
therapies and about associated predictors remains poor. The MYRACLE cohort, a multicenter
prospective cohort of patients with MM, is set up to address this limitation.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Nantes University Hospital - 44093 - Nantes - France | Cyrille TOUZEAU, PU | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| La Roche sur Yon Hospital Departmental - 85000 - La Roche-sur-Yon - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Patient with diagnosis of multiple myeloma according to standard criteria
- Age >18
- Patient with diagnosis of multiple myeloma according to standard criteria
- Age >18
- Minor patient
- Patient under guardianship
- Protected patient